However, based on current literature, a panel with the following genes will most likely be informative in clinical assessment for most of the myeloid neoplasms: FLT3, NPM1, CEBPA, TP53, IDH1/2, DNMT3A, TET2, CSF3R, SRSF2, KIT, NRAS, RUNX1, WT1, ASXL1, SF3B1 for AML; NRAS, KRAS, IDH1/2, TET2, EZH2, ASXL1, RUNX1, TP53, DNMT3A, SF3B1, U2AF1, ETV6 for MDS; JAK2, CALR, MPL, IDH1/2, ASXL1, TET2, EZH2, SRSF2, SF3B1, TP53for MPN; TET2, SRSF2, ASXL1, RUNX1, NRAS, TP53 for CMML; SF3B1 for MD/MPN RS-T; CSF3R for CNL, SETBP1 for aCML, KIT (D816V) for mast cell disease. This evidence concerns the gene EZH2 and myeloid neoplasm.